[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381788-105":59,"doc-detail-381788-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","prediction-of-stent-failure-for-malignant-ureteral-obstruction-in-non-urological-cancer","Prediction of Stent Failure for Malignant Ureteral Obstruction in Non-Urological Cancer","","Prediction model for stent failure in malignant ureteral obstruction (MUO) due to non-urological cancers, developed from retrospective review of MUO inpatients treated with ureteral stenting or percutaneous nephrostomy (PCN) between 2006 and 2014. Cox regression identified prognostic variables, and multivariate analysis selected bladder invasion and prior estimated glomerular filtration rate (eGFR) as significant predictors. Patients were stratified into low-, intermediate-, and high-risk groups with markedly different stent failure-free survival. Results support PCN as the primary procedure when bladder invasion and low eGFR coexist.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prediction-of-stent-failure-for-malignant-ureteral-obstruction-in-non-urological-cancer/381788/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prediction-of-stent-failure-for-malignant-ureteral-obstruction-in-non-urological-cancer/381788.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this study?","Question",{"text":113,"@type":114},"To identify prognostic factors linked to ureteral stent failure and to build a prediction model for MUO inpatients with non-urological cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which patients and treatments were included?",{"text":118,"@type":114},"Patients with non-urological malignancies who underwent ureteral stenting or percutaneous nephrostomy (PCN) for MUO between 2006 and 2014 were included.",{"name":120,"@type":111,"acceptedAnswer":121},"What predictors were significant in the multivariate analysis?",{"text":122,"@type":114},"Bladder invasion and previous eGFR were significant predictors of stent failure-free survival.",{"name":124,"@type":111,"acceptedAnswer":125},"What management recommendation did the study support?",{"text":126,"@type":114},"For MUO caused by non-urological cancers, patients with bladder invasion and low eGFR showed poor stent failure-free survival, so PCN should be considered the primary procedure.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},381788,1790318530,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":105},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Article  \nYonsei Med J 2023 Nov;64(11):665-669 [https://doi.org/10.3349/ymj.2023.0117](https://doi.org/10.3349/ymj.2023.0117)  \npISSN: 0513-5796 · eISSN: 1976-2437  \n\n| Prediction of Stent Failure for Malignant Ureteral Obstruction in Non-Urological Cancer\u003Cbr>JiEun Heo, Dae Young Jeon, Jongsoo Lee, Hyun Ho Han, and Won Sik Jang\u003Cbr>Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. |\n| --- |\n| Purpose: To analyze prognostic factors associated with ureteral stent failure and to develop a prediction model for malignant ureteral obstruction (MUO) inpatients with non-urological cancers.\u003Cbr>Materials and Methods: We retrospectively reviewed patients with non-urological cancers who underwent ureteral stenting or percutaneous nephrostomy (PCN) for MUO between 2006 and 2014. Variables predicting stent failure were identified using Cox regression analysis.\u003Cbr>Results: Of the 743 patients, 468 (63.0%) underwent ureteral stenting only, and 275 (37.0%) underwent PCN owing to technical (n=215) or functional (n=60) stent failure. The median overall survival was 4 [interquartile range (IQR) 1–11] months, and the median interval duration to stent failure was 2 (IQR 0–7) months. In univariate analysis, lower gastrointestinal cancer, previous radiotherapy to the pelvis, bladder invasion, lower ureteral obstruction, and low previous estimated glomerular filtration rate (eGFR)(\u003C30 mL/min/1.73 m2) were significantly associated with a decreased survival rate. In multivariate analysis, bladder invasion and previous eGFR were significant predictors. With these two predictors, we divided patients into three groups based on their presence: low-risk (neither factor; n=516), intermediate-risk (one factor; n=206), and high-risk (both factors; n=21). The median stent failure-free survival rates of patients in the low-, intermediate-, and high-risk groups were 26 (8-unreached), 1 (0–18), and 0 (0–0) months, respectively (p\u003C0.001).\u003Cbr>Conclusion: In cases of ureteral obstruction caused by non-urological cancers, patients with bladder invasion and a low eGFR showed poor stent failure-free survival. Therefore, PCN should be considered the primary procedure for these patients.\u003Cbr>KeyWords: Percutaneous nephrostomy, survival, ureteral obstruction, urinary diversion |\n\nINTRODUCTION  \nMalignant ureteral obstruction (MUO), caused by intrinsic or extrinsic malignant lesions, is usually associated with advanced cancer. The presence of MUO is considered a poor prognostic factor because patients with MUO have a short median survival time (6.4 months).1-4 If the obstruction isnot decompressed,  \nReceived: April 28, 2023 Revised: July 13, 2023  \nAccepted: August 15, 2023 Published online: October 17, 2023  \nCorresponding author: Won Sik Jang, MD, PhD, Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  \nE-mail: [sindakjang@yuhs.ac](sindakjang@yuhs.ac)  \n•The authors have no potential conflicts of interest to disclose.© Copyright: Yonsei University College of Medicine 2023  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)[ ](https://creativecommons.org/licenses/)[by-nc/4.0](by-nc/4.0)) [which](which) permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nobstructive uropathy can lead to renal insufficiency, uremia, urosepsis, or even death.5 Urinary diversion, including percutaneous nephrostomy (PCN) and ureteral stent placement, is generally performed to treat MUO. With advances in endourologic devices and materials, ureteral stents have become the gold standard material for MUO treatment.6 However, a highstent failure rate has been reported, and PCN is still used as either a primary or seconda","cbCaitedpIjbmv0t","https://ap.wps.com/l/cbCaitedpIjbmv0t","pdf",201518,"English","# Purpose\n# Materials and Methods\n# Results\n# Conclusion","[{\"question\":\"What was the purpose of this study?\",\"answer\":\"To identify prognostic factors linked to ureteral stent failure and to build a prediction model for MUO inpatients with non-urological cancers.\"},{\"question\":\"Which patients and treatments were included?\",\"answer\":\"Patients with non-urological malignancies who underwent ureteral stenting or percutaneous nephrostomy (PCN) for MUO between 2006 and 2014 were included.\"},{\"question\":\"What predictors were significant in the multivariate analysis?\",\"answer\":\"Bladder invasion and previous eGFR were significant predictors of stent failure-free survival.\"},{\"question\":\"What management recommendation did the study support?\",\"answer\":\"For MUO caused by non-urological cancers, patients with bladder invasion and low eGFR showed poor stent failure-free survival, so PCN should be considered the primary procedure.\"}]","Prediction of Stent Failure for Malignant Ureteral Obstruction in Non-Urological Cancer | PDF",1790247051]